Seeking Alpha

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...
The Post-Journal

Oversized Plants, Entities Run Empty On Promises

Despite hopes for a production facility for ImmunityBio, the town of Dunkirk plant off Route 5 is an empty ghost town. Standing in front of the Tesla Gigafactory in South Buffalo in the middle of July ...
Business Wire

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...
Benzinga.com

What's Going On With ImmunityBio Shares Tuesday?

ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading higher Tuesday after the company announced its chemotherapy-free combination showed 100% disease control results and is planning a Phase 2 trial.
Hosted on MSN

Why is ImmunityBio stock back in retail spotlight today?

・ImmunityBio reported lasting responses in a blood cancer study. ・The company expects a U.S. filing for its bladder cancer program by the end of 2026. ・Saudi regulators granted new approvals for ...